

# A Paradigm Shift for the Amino Acid Editing Mechanism of Human Cytoplasmic Leucyl-tRNA Synthetase<sup>†</sup>

Yan Ling Joy Pang and Susan A. Martinis\*

*Department of Biochemistry, University of Illinois, 419 Roger Adams Laboratory, Box B-4, 600 South Matthews Avenue, Urbana, Illinois 61801*

*Received June 30, 2009; Revised Manuscript Received August 13, 2009*

**ABSTRACT:** Leucyl-tRNA synthetase (LeuRS) has been identified as a target for a novel class of boron-containing small molecules that bind to its editing active site. When the 3' end of tRNA<sup>Leu</sup> binds to the editing active site, the boron cross-links to the *cis*-diols of its terminal ribose. The cross-linked RNA–protein complex blocks the overall aminoacylation activity of the enzyme. Similar to those of other LeuRSs, the human cytoplasmic enzyme (hscLeuRS) editing active site resides in a discrete domain called the connective polypeptide 1 domain (CPI), where mischarged tRNA binds for hydrolysis of the noncognate amino acid. The editing site of hscLeuRS includes a highly conserved threonine discriminator and universally conserved aspartic acid that were mutationally characterized. Substitution of the threonine residue to alanine uncoupled specificity as in other LeuRSs. However, the introduction of bulky residues into the amino acid binding pocket failed to block deacylation of tRNA, indicating that the architecture of the amino acid binding pocket is different compared to that of other characterized LeuRSs. In addition, mutation of the universally conserved aspartic acid abolished tRNA<sup>Leu</sup> deacylation. Surprisingly though, this editing-defective hscLeuRS maintained fidelity. It is possible that an alternate editing mechanism may have been activated upon failure of the post-transfer editing active site.

Aminoacyl-tRNA synthetases (aaRSs)<sup>1</sup> establish the genetic code by accurately linking the correct tRNA to its cognate amino acid in the first step of translation (1, 2). In a two-step reaction mechanism, each aaRS ensures that the tRNA is correctly charged.



The charged tRNAs are then shuttled to the ribosome via elongation factors. To protect against statistical errors that could be incorporated into proteins during translation, approximately half of the family of aaRSs have evolved proofreading mechanisms (2, 3). These fidelity mechanisms are critical to the cell. Defects in aaRS editing result in cell death (4–6) and neurological disease in mammals (7).

Leucyl-tRNA synthetase (LeuRS) must accurately discriminate leucine from a number of standard and nonstandard amino acids (5). The canonical core of LeuRS contains an aminoacylation active site that activates cognate amino acids as well as structurally similar noncognate amino acids that include isoleucine and valine. A polypeptide called the connective polypeptide 1 (CPI) domain (8) is inserted into the core via two  $\beta$ -strand linkers (9). The LeuRS CPI domain functions as a second

“fine sieve” (10) that excludes correctly charged amino acids but hydrolyzes misaminoacylated tRNA (11–14). This bidomain architecture that provides a double sieve to enhance fidelity is reminiscent of all editing aaRSs. Synthetic sites and CPI editing domains that are homologous to LeuRS are also specifically found in isoleucyl-tRNA synthetase (IleRS) and valyl-tRNA synthetase (ValRS) (15).

The editing active sites for the CPI domains of IleRS, ValRS, and LeuRS are comprised of conserved peptides that are only partially differentiated to confer specificity (16). Each contains a universally conserved aspartic acid that is essential for hydrogen bonding to the amino group of the bound amino acid (Figure 1). Hydrolytic editing activity is abolished when the aspartate is substituted with an alanine in LeuRS (17), ValRS (18), and IleRS (19).


In addition, a threonine-rich region is important for catalysis and substrate specificity. One of these threonines in LeuRS functions specifically as a specificity determinant. Substitution of this conserved threonine with an alanine abolishes editing specificity by removing a steric hindrance in the editing pocket to facilitate leucine binding (14). Thus, correctly charged Leu-tRNA<sup>Leu</sup> is hydrolyzed in the second sieve before undergoing product release. Substitution of this conserved threonine with a bulky residue in *Escherichia coli* LeuRS blocks amino acid editing, resulting in a mischarging phenotype (11, 20).

In many higher organisms, and even some archae and yeast, aaRS operates as a large or small complex. For example, in human cells, the aaRS macromolecular complex contains nine aaRSs, including the lysyl-, aspartyl-, methionyl-, glutamyl-, prolyl-, isoleucyl-, leucyl-, arginyl-, and glutaminyl-tRNA synthetases (21). We wondered if viable editing mechanisms that typically reside in separate domains such as the CPI editing

<sup>†</sup>This work was supported by National Institutes of Health Grant GM063789.

\*To whom correspondence should be addressed. Phone: (217) 244-2405. Fax: (217) 244-5858. E-mail: martinis@life.uiuc.edu.

<sup>1</sup>Abbreviations: aaRSs, aminoacyl-tRNA synthetases; tRNA, transfer RNA; hscLeuRS, human cytoplasmic leucyl-tRNA synthetase; IleRS, isoleucyl-tRNA synthetase; ValRS, valyl-tRNA synthetase; CPI, connective polypeptide 1; I4, insertion 4; PDB, Protein Data Bank.



**FIGURE 1:** Multiple-sequence alignment of the LeuRS editing pocket and crystal structure of hscLeuRS CP1 domain. (A) Sequence alignment of conserved regions within the LeuRS editing pocket. The threonine specificity determinant (T298) and universally conserved aspartate (D399) in hscLeuRS are indicated by arrows. Highly conserved residues are highlighted in black. Two shades of gray distinguish homologous amino acid sites. Abbreviations: *Hs*, *Homo sapiens*; *Bt*, *Bos taurus*; *Rn*, *Rattus norvegicus*; *Ec*, *E. coli*; *Tt*, *Thermus thermophilus*; *Mt*, *Mycobacterium tuberculosis*; *Sc*, *Saccharomyces cerevisiae*; *Nc*, *Neurospora crassa*; c, cytoplasmic; m, mitochondrial. (B) Crystal structure of the hscLeuRS CP1 domain (PDB entry 2WFD) showing the editing pocket containing the threonine-rich region and the universally conserved aspartate. Residues Thr<sup>293</sup>, Leu<sup>294</sup>, Thr<sup>298</sup>, Val<sup>392</sup>, Asp<sup>399</sup>, Val<sup>431</sup>, and Val<sup>479</sup> are shown in space-filling form. The atoms are colored as follows: red for oxygen, light blue for nitrogen, and gray for carbon. Thr<sup>298</sup> is highlighted completely in yellow. The I4 insertion is highlighted in blue.

module might be maintained in human aaRSs that are confined to the complex. The primary structure of human cytoplasmic LeuRS (hscLeuRS) retains key amino acids in the editing active site that are important to bacterial LeuRS editing activities, although other sites within the region have diverged (Figure 1). For example, recent crystal structure information for the hscLeuRS editing domain shows that two residues have diverged to bulkier residues, leading to a smaller hydrophobic pocket within the CP1 domain of hscLeuRS (22). Eukaryotic cytosolic LeuRS has also been found to contain an I4 insertion in the CP1 domain that was hypothesized to function as a lid by closing over the editing pocket. This would result in a capped tighter hydrophobic editing pocket for hscLeuRS compared to the more spacious bacterial LeuRS pocket that is open to the environment (22).

We cloned the hscLeuRS gene and expressed it in *E. coli* independent of the multi-aaRS complex. Despite maintaining key features in the editing active site that are critical to its

hydrolytic activity, mutational analysis of the human enzyme suggests that it has functionally differentiated to maintain fidelity.

## EXPERIMENTAL PROCEDURES

**Materials.** Oligonucleotide primers were purchased from Integrated DNA Technologies (Coralville, IA). Restriction enzymes *DpnI* and *BstNI* were obtained from Promega (Madison, WI) and New England BioLabs Inc. (Beverly, MA), respectively. Cloned *Pfu* DNA polymerase and dNTP mix were acquired from Stratagene (La Jolla, CA). Crude calf liver tRNA was purchased from Novagen (San Diego, CA). Tritium-labeled amino acids, as well as [<sup>32</sup>P]ATP and [<sup>32</sup>P]PP<sub>i</sub>, were obtained from Amersham Pharmacia Biotech (Piscataway, NJ). The pHSLARS1 plasmid was a gift from W. Mao and K. Alley (Anacor Pharmaceuticals, Palo Alto, CA).

**RNA Preparation.** The CCA 3' end of crude calf liver tRNA was added via a nucleotidyl transferase reaction. The pCCA plasmid encoding the nucleotide transferase enzyme was a gift from P. Schimmel (The Scripps Research Institute, La Jolla, CA). The enzyme was expressed in BL21 cells for 3 h at 37 °C with 1 mM isopropyl β-D-thiogalactopyranoside (IPTG) and then purified over a nickel affinity column (Sigma, St. Louis, MO). Each nucleotidyl transferase reaction mixture contained 100 mM glycine (pH 9.0), 10 mM MgCl<sub>2</sub>, 1 mM dithiothreitol (DTT), 100 μM ATP, 100 μM CTP, 10 mg/mL crude calf liver tRNA, and 5 μM *E. coli* CCA nucleotidyl transferase and was incubated in a 70 °C heat block for 15 min. Protein was removed from the mixture by extraction with a phenol/chloroform/isoamyl alcohol mixture (125:24:1) (Fisher Biotech, Fair Lawn, NJ) that was pre-equilibrated at pH 4.3. The tRNA was then ethanol precipitated and resuspended in nuclease-free water (Ambion, Austin, TX).

*E. coli* leucyl-tRNA<sup>Leu</sup><sub>UAA</sub> (tRNA<sup>Leu</sup>) was transcribed from the plasmid pDNAleu (23) that encoded the gene for *E. coli* tRNA<sup>Leu</sup>. A total of 450 μg of plasmid pDNAleu was first digested overnight with 25 units of *BstNI* at 60 °C in a total volume of 1 mL and then used as a template for runoff transcription (24). T7 RNA polymerase was expressed for 3 h at 37 °C with 1 mM IPTG and then purified over a nickel column. Each transcription mixture contained 40 mM tris-(hydroxymethyl)aminomethane (Tris) (pH 8.0), 30 mM MgCl<sub>2</sub>, 5 mM DTT, 0.01% Triton X-100, 50 μg/mL bovine serum albumin (BSA), NTPs (4 mM each), 80 mg/mL PEG8000, 0.02 unit/μL RNase inhibitor (Eppendorf, Hamburg, Germany), 2 mM spermidine, 0.01 mg/mL pyrophosphatase (Sigma), and 0.8 μM T7 RNA polymerase. The reaction mixtures were incubated at 42 °C for 3 h followed by a second addition of 0.8 μM T7 RNA polymerase and then incubated for an additional 3 h.

The reaction mixtures were precipitated with twice the volume of 100% ethanol and with 167 μg/mL glycogen as a carrier at −80 °C for at least 30 min. The RNA products were purified by electrophoresis on a 10% polyacrylamide gel that contained 8 M urea. The tRNA<sup>Leu</sup> band was visualized by UV shadowing and excised from the gel. The excised gel was crushed and soaked in 0.5 M NH<sub>4</sub>OAc and 1 mM ethylenediaminetetraacetic acid (EDTA, pH 8.0) and rocked gently at 37 °C to extract the tRNA. The supernatant was collected and the gel extracted two more times. Butanol extraction was used to concentrate the tRNA, which was then ethanol precipitated and resuspended in nuclease-free water (Ambion). The concentration of the tRNA was calculated on the basis of its extinction coefficient of 840700 L mol<sup>−1</sup> cm<sup>−1</sup> (25).

**Mutagenesis.** Site-directed mutagenesis was performed via the polymerase chain reaction (PCR) using the template plasmid pHSLARS1 that encoded the wild-type *H. sapiens* cytoplasmic LeuRS (hscLeuRS) gene. This plasmid was utilized to make mutants, including T298A (pJPT298A) using primers T298A-Fwd (5'-CAG ACC TGA GGC CAT GTT TGG GC-3') and T298A-Rev (5'-GCC CAA ACA TGG CCT CAG GTC TG-3'), T298Y (pJPT298Y) using primers T298Y-Fwd (5'-CAG ACC TGA GTA CAT GTT TGG GC-3') and T298Y-Rev (5'-GCC CAA ACA TGT ACT CAG GTC TG-3'), and D399A (pJPD399A) using primers D399A-Fwd (5'-CTC CCC TGA TGC TAT TGC TGC CC-3') and D399A-Rev (5'-GGG CAG CAA TAG CAT CAG GGG AG-3'). Each 50  $\mu$ L PCR mixture contained 50 ng of DNA template, 100 ng each of forward and reverse primer, 200  $\mu$ M dNTPs, and 2.5 units of *Pfu* DNA polymerase in commercial buffer. Each PCR was conducted at 95 °C for 30 s, 55 °C for 30 s, and 68 °C for 30 min for one cycle and then 16 cycles at 95 °C for 30 s, 58 °C for 30 s, and 68 °C for 22 min. The reaction was completed with a final incubation at 68 °C for 22 min. A restriction digestion of each PCR mixture with 20 units of *DpnI* was conducted for 4 h at 37 °C and then used for transformation of *E. coli* DH5 $\alpha$ . The mutant sequences of the LeuRS genes were confirmed by DNA sequencing (UIUC Core Sequencing Facility, Urbana, IL).

**Expression and Purification of hscLeuRS.** Mutant and wild-type plasmids were used to transform *E. coli* strain BL21-(DE3) codon PLUS (Stratagene). A single colony was used to inoculate a 3 mL culture of LB with 100  $\mu$ g/mL ampicillin and grown overnight at 37 °C. This 3 mL aliquot was then transferred to 1 L of LB containing 100  $\mu$ g/mL ampicillin and grown at 37 °C until the OD<sub>600</sub> was between 0.6 and 1.0. Protein expression was induced overnight at room temperature by the addition of 1 mM IPTG.

The next day, cells were harvested by centrifugation at 6000 rpm for 15 min in an Avanti J-E centrifuge (Beckman Coulter, Fullerton, CA). The cell pellet was resuspended in 7 mL of HA-1 buffer [20 mM NaP<sub>i</sub>, 10 mM Tris (pH 8.0), 300 mM NaCl, 5 mM imidazole, and 5% glycerol] and then sonicated once at 50% power using a Vibra Cell sonicator (Sonic, Newtown, CT). The lysate was spun at 12000 rpm for 30 min at 4 °C. The supernatant was collected and the pellet discarded.

The supernatant containing hscLeuRS was combined with a HIS-Select HF Nickel Affinity (Sigma) resin that had been pre-equilibrated with HA-1 buffer. The supernatant was rocked gently with the nickel resin for 2 h at 4 °C to allow the N-terminally fused six-histidine tag on each protein to bind to the resin. The resin was then washed with a total of 100 mL of HA-2 buffer [20 mM NaP<sub>i</sub>, 10 mM Tris (pH 8.0), 500 mM NaCl, 5 mM imidazole, and 5% glycerol], and the protein was eluted with 10 mL of 100 mM imidazole in HA-1 buffer. The protein solution was dialyzed against a 100 mM KP<sub>i</sub> (pH 6.8), 10 mM  $\beta$ -mercaptoethanol, 50% glycerol buffer and stored at -20 °C. The concentration of protein was determined on the basis of its absorbance at 280 nm and calculated using an estimated extinction coefficient of 178080 L mol<sup>-1</sup> cm<sup>-1</sup> computed by the Expasy ProtParam tool (<http://ca.expasy.org/tools/protparam.html>).

**Aminoacylation Assays.** Each aminoacylation reaction mixture contained 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid-KOH (HEPES) (pH 7.6), 30 mM KCl, 30 mM MgCl<sub>2</sub>, 0.02% BSA, 1 mM DTT, 4 mg/mL calf liver tRNA, 22  $\mu$ M [<sup>3</sup>H]leucine (158 Ci/mmol), and 500 nM enzyme.

Misaminoacylation assays were conducted in the same manner except with 1  $\mu$ M enzyme, 20  $\mu$ M *E. coli* transcribed tRNA<sup>Leu</sup>, and 22  $\mu$ M [<sup>3</sup>H]isoleucine (93 Ci/mmol). Reactions were initiated with 4 mM ATP and conducted in a 30 °C heat block. Aliquots (20  $\mu$ L) were taken at different time points and quenched on Whatman filter pads that were presoaked with 5% trichloroacetic acid (TCA). The pads were washed three times for 10 min each with cold 5% TCA, once with cold 70% ethanol, and once with anhydrous ether. The washed pads were then dried under a heat lamp. Radioactivity was quantified in a Beckman LS 6000IC scintillation counter (Beckman Coulter, Fullerton, CA).

**Deacylation Assays.** Transcribed *E. coli* tRNA<sup>Leu</sup> at a final concentration of 8  $\mu$ M was aminoacylated with 1  $\mu$ M wild-type *E. coli* LeuRS or misaminoacylated with 1  $\mu$ M editing-defective *E. coli* LeuRS in a reaction mixture containing 60 mM Tris (pH 7.5), 10 mM MgCl<sub>2</sub>, 1 mM DTT, and 4 mM ATP. The reactions were conducted at room temperature for either 60 min (aminoacylation) or 180 min (misaminoacylation) and then quenched with 0.18% acetic acid (26). Protein was removed from the mixture by a phenol/chloroform/isoamyl alcohol mixture (125:24:1) (Fisher Biotech) at pH 4.3. The charged tRNA was then ethanol precipitated and resuspended in 50 mM KP<sub>i</sub> (pH 5.0).

Deacylation reaction mixtures each contained 60 mM Tris (pH 7.5), 10 mM MgCl<sub>2</sub>, 300 mM KCl, and approximately 4  $\mu$ M [<sup>3</sup>H]Ile-tRNA<sup>Leu</sup> or [<sup>3</sup>H]Leu-tRNA<sup>Leu</sup>. Reactions were conducted in a 30 °C heat block and initiated with 500 nM enzyme. Aliquots (10  $\mu$ L) were taken at different time points and quenched on Whatman filter pads that were presoaked with 5% TCA. The pads were washed and analyzed as described above.

**Inorganic Pyrophosphate (PP<sub>i</sub>) Exchange Assays.** Reactions of mixtures containing 50 mM HEPES (pH 8.0), 10 mM MgCl<sub>2</sub>, 300 mM KCl, 1 mM DTT, 1 mM [<sup>32</sup>P]PP<sub>i</sub> (78 mCi/mL) (Amersham Pharmacia Biotech), 1 mM leucine, and 1  $\mu$ M enzyme were initiated with 1 mM ATP. Aliquots (2  $\mu$ L) were taken at different time points and spotted on a cellulose polyethyleneimine (PEI) thin-layer chromatography (TLC) plate (Scientific Adsorbents Inc., Atlanta, GA). The reaction components were separated by TLC in 750 mM KH<sub>2</sub>PO<sub>4</sub> (pH 3.5) and 4 M urea (27). The separated radiolabeled bands were visualized by phosphorimaging using FUJIX BAS 1000 film (FUJIFILM Medical Systems U.S.A., Stamford, CT) and quantified with a Storm 840 molecular dynamics imager (GE Healthcare, Piscataway, NJ).

**ATPase Assays.** Each reaction mixture contained 100 mM Tris (pH 7.5), 20 mM MgCl<sub>2</sub>, 10 mM DTT, 5 mM amino acid, 36.2  $\mu$ M [ $\alpha$ -<sup>32</sup>P]ATP (3000 Ci/mmol), and 10  $\mu$ M *E. coli*-transcribed tRNA. The reactions were initiated with 1  $\mu$ M enzyme. Aliquots (2  $\mu$ L) were taken at different time points and spotted on a cellulose PEI TLC plate (Scientific Adsorbents Inc.). The reaction components were separated by TLC in 750 mM KH<sub>2</sub>PO<sub>4</sub> (pH 3.5). The separated radiolabeled bands were visualized by phosphorimaging using FUJIX BAS 1000 film (FUJIFILM Medical Systems U.S.A.) and quantified with a Storm 840 molecular dynamics imager (GE Healthcare).

## RESULTS

The editing active site within the CP1 domain of LeuRS is marked by conserved peptide motifs. A highly conserved threonine within a threonine-rich region acts as a specificity determinant (Figure 1A) and blocks leucine from binding for hydrolysis



of correctly charged Leu-tRNA<sup>Leu</sup>. Substitution of this key threonine with a bulky residue such as tyrosine fills up the amino acid binding pocket in *E. coli* LeuRS to prevent editing (11, 20). In a separate motif, a universally conserved aspartic acid (Figure 1A) that is also found in IleRS and ValRS anchors the amino acid via a hydrogen bond with its amino moiety in the active site. Substitution of the aspartic acid with alanine abolishes editing activity in LeuRS and IleRS (17–19).

The threonine specificity determinant and universal aspartic acid are also found in hscLeuRS among many other conserved features of the editing active site. This suggests that LeuRS from a higher eukaryote maintains fidelity using an editing active site architecture that is common to lower organisms. We tested this hypothesis by substituting the conserved threonine at position 298 of hscLeuRS (Thr<sup>252</sup> in *E. coli* LeuRS) with an alanine (T298A) and also with a bulky tyrosine (T298Y). The universal aspartate at position 399 in hscLeuRS was also substituted with an alanine. The mutant and wild-type proteins were expressed in *E. coli* and purified by affinity chromatography with a six-histidine tag.

The enzymatic activities for each of the mutants were characterized and compared to that of wild-type hscLeuRS. Both the T298Y and D399A mutant hscLeuRSs exhibited robust aminoacylation of crude calf liver tRNA, though the latter activity was

reduced compared to the wild-type activity (Figure 2A). As would be expected on the basis of analysis of other LeuRSs (14), the T298A LeuRS mutant failed to accumulate Leu-tRNA<sup>Leu</sup> (Figure 2A). The T298A hscLeuRS mutant also uncouples specificity in the editing active site and hydrolyzes Leu-tRNA<sup>Leu</sup> (Figure 2B).

We wondered if the relatively reduced aminoacylation activities of the D399A LeuRS mutant enzyme might be due in part to changes in amino acid activation reaction step even though the mutation is located in the CP1 domain, which is completely separate from the canonical aminoacylation core. Pyrophosphate exchange assays determined that the D399A LeuRS mutant activated leucine at reduced rates (Figure 3). The decrease in leucine-dependent pyrophosphate exchange activity by the distal D399A mutation was largely due to a  $K_M$  effect (Table 1). The  $K_M$  was ~40-fold higher for leucine activation by the D399A LeuRS mutant ( $0.9 \pm 0.2$  mM) as compared to the human wild-type enzyme ( $0.024 \pm 0.009$  mM). The  $k_{cat}$  values for leucine activation of the wild-type and mutant enzymes were  $2.1 \pm 0.4$  and  $5.6 \pm 0.1$  s<sup>-1</sup>, respectively. This reduction in amino acid activation activity is consistent with the lower levels of leucylation activity for the D399A LeuRS mutant compared to the wild-type enzyme. These results suggest that a long-distance interdomain communication mechanism for the protein exists between the aminoacylation and amino acid editing active site that is at least partially independent of tRNA.

Mischarged *E. coli* Ile-tRNA<sup>Leu</sup> was isolated to test the wild-type and mutant LeuRSs directly for tRNA deacylation activity. The D399A mutant of LeuRS eliminated Ile-tRNA<sup>Leu</sup> deacylation activity (Figure 4), which is consistent with all other alanine substitutions at this key site in LeuRS (17), IleRS (19), and ValRS (18). In contrast, though, substitution of the conserved threonine with a bulky tyrosine residue (T298Y) in hscLeuRS maintained Ile-tRNA<sup>Leu</sup> deacylation activity. This suggests that even though the threonine specificity determinant is maintained, the architecture around the amino acid binding pocket has changed for the human enzyme. A recent crystal structure for




FIGURE 2: Leucine aminoacylation and deacylation by wild-type and mutant hscLeuRS. (A) Leucylation activity was measured with 500 nM enzyme and 4 mg/mL crude calf liver tRNA (Novagen, Gibbstown, NJ). (B) Post-transfer editing reactions were conducted with 500 nM enzyme and ~4  $\mu$ M *E. coli* Leu-tRNA<sup>Leu</sup>. All enzyme reaction mixtures were incubated at 30 °C. Wild-type (WT) and mutant proteins are represented by the following symbols: WT (●), T298A (○), D399A (△), T298Y (■), and no enzyme (○). Error bars are based on the results of three reactions each and indicated for each point.




FIGURE 3: Pyrophosphate (PP<sub>i</sub>) exchange activity of wild-type and D399A hscLeuRS. Leucine-dependent PP<sub>i</sub> exchange assays were conducted with 1  $\mu$ M hscLeuRS and 10 mM leucine: wild type with leucine (■) and D399A with leucine (●). Error bars are based on the results of three reactions each and indicated for each point.

Table 1: Apparent Kinetic Parameters for Amino Acid Activation

enzyme	$K_M$ (mM)		$k_{cat}$ (s <sup>-1</sup> )		$k_{cat}/K_M$ (s <sup>-1</sup> mM <sup>-1</sup> )	
	Leu	Ile	Leu	Ile	Leu	Ile
wild-type Hsc	$0.024 \pm 0.0089$	$2.04 \pm 0.80$	$2.1 \pm 0.43$	$0.34 \pm 0.17$	$94.3 \pm 23.4$	$0.16 \pm 0.035$
D399A Hsc	$0.90 \pm 0.19$	$3.3 \pm 1.2$	$5.6 \pm 0.067$	$0.51 \pm 0.044$	$5.6 \pm 0.40$	$0.17 \pm 0.043$




FIGURE 4: Deacylation activity of wild-type and mutant hscLeuRS. Post-transfer editing assays were conducted with 500 nM enzyme and  $\sim 4 \mu\text{M}$  *E. coli* Leu-tRNA<sup>Leu</sup> at 30 °C. Wild-type (WT) and mutant proteins are represented by the following symbols: WT (▼), T298A (◆), D399A (△), T298Y (■), and no enzyme (●). Error bars are based on the results of three reactions each and indicated for each point.

the CP1 domain of hscLeuRS and the related yeast cytoplasmic enzyme showed that the eukaryotic LeuRS CP1 domain has acquired insertions (22). In particular, the I4 insertion (colored blue in Figure 1B) is juxtaposed with the editing active site and has been hypothesized to act as a lid to sequester substrate in the hydrolytic pocket (22). It is possible that closing the I4 insertion lid might promote an induced fit for the mischarged tRNA<sup>Leu</sup> to be edited, even in the presence of a bulky residue substitution in the human LeuRS editing site.

In the absence of deacylation activity, we expected that the mutant D399A hscLeuRS would mischarge tRNA<sup>Leu</sup> similar to other editing-defective LeuRSs (17–19). Crude calf liver tRNA was mischarged by the D399A LeuRS mutant, but only at low levels (data not shown) despite a robust aminoacylation activity (Figure 2A). By comparison, crude *E. coli* tRNA was mischarged at higher levels (Figure 5A) with a  $k_{\text{cat}}$  of  $0.0018 \pm 0.0005 \text{ s}^{-1}$  by the D399A hscLeuRS mutant, albeit more weakly than LeuRS mutants from other origins that had ablated the tRNA deacylation activity. The D399A LeuRS mutant failed to charge isoleucine in *in vitro*-transcribed *E. coli* tRNA<sup>Leu</sup>, even at high concentrations of  $1 \mu\text{M}$  enzyme (Figure 5B). This suggests that the low levels of mischarging activity are dependent on tRNA modifications. It is possible that these RNA modifications stabilize tertiary structure to facilitate RNA–protein interactions for aminoacylation. As would be expected, wild-type hscLeuRS maintained fidelity and did not mischarge crude or transcribed *E. coli* tRNA.

We hypothesized that, similar to the long-distance effect by the D399A mutation on leucine activation (Figure 3), isoleucine activation might also be significantly inhibited, resulting in only low mischarging activities for the editing-defective enzyme. However, the D399A mutation had a much less pronounced effect on the  $K_M$  and  $k_{\text{cat}}$  for isoleucine-dependent pyrophosphate exchange activity, with  $k_{\text{cat}}/K_M$  values that were nearly equivalent for the wild-type and mutant enzymes (Table 1). Thus, these long-distance interdomain effects between the editing and aminoacylation active sites are sensitive to the cognate amino acid. It is also possible that low misaminoacylation activity of the D399A hscLeuRS could be due to a redundant fidelity mechanism that originates in the aminoacylation active site. In the absence of tRNA, isoleucine stimulated the D399A mutant hscLeuRS to form AMP with a  $k_{\text{cat}}$  of  $0.06 \pm 0.02 \text{ s}^{-1}$  and a  $K_M$  of  $1.8 \pm 0.5 \text{ mM}$  in ATPase assays. If this represents a case of a putative pretransfer editing pathway, then the mechanism would be independent of the D399A mutation in hscLeuRS since the activated isoleucyl-adenylates would be directly cleaved in or expelled from the aminoacylation active site.




FIGURE 5: Mischarging activity of wild-type and mutant hscLeuRS with transcribed and crude *E. coli* tRNA. (A) Misaminoacylation reactions were conducted with  $1 \mu\text{M}$  enzyme and 4 mg/ml crude *E. coli* tRNA. (B) Misaminoacylation reactions were conducted with  $1 \mu\text{M}$  enzyme and  $20 \mu\text{M}$  *in vitro* transcribed *E. coli* tRNA. Wild-type (WT) and mutant proteins are represented by the following symbols: WT (▼), D399A (△), and an editing-deficient *E. coli* LeuRS mutant (□). Error bars are based on the results of three reactions each and indicated for each point.

## DISCUSSION

Representative of all LeuRSs, the hscLeuRS contains specific active sites for aminoacylation and editing that are located in separate domains. X-ray crystal structures for LeuRSs from all three kingdoms (22, 28, 29) have shown that within the CP1 editing domain, the LeuRS editing active site is marked by a threonine-rich peptide. In the human enzymes, it includes the highly conserved Thr<sup>298</sup> specificity determinant (Thr<sup>252</sup> in *E. coli* LeuRS) as well as Thr<sup>293</sup> (Thr<sup>247</sup> in *E. coli* LeuRS) that has been shown to be important in orienting the editing substrate in the editing active site for catalysis by LeuRS (30). It also has the “GTG adenine-binding region” as well as a universally conserved aspartic acid that interacts with the amino group of the bound amino acid (17). However, four peripheral peptide insertions distinguish the hscLeuRS and other eukaryotic CP1 domains from their bacterial counterparts. X-ray crystallography structures for the hscLeuRS and yeast cytoplasmic LeuRS show that although the integrity of the editing core is clearly maintained, these peripheral insertions appear to induce some local structural rearrangements (22).

The I4 peptide insertion in the LeuRS CP1 domain is hypothesized to cap the editing active site when mischarged tRNA is bound (22). Another insertion, called I2, contacts the bound editing substrate analogue. In the yeast cytoplasmic LeuRS CP1 domain structure, the I2 insert also interacts with a network of water molecules. It is possible then that displacement of these water molecules could provide some plasticity for the editing active site to facilitate an induced fit mechanism. In the case of our results, water molecules could be displaced by the introduction of the bulky tyrosine residue at the Thr<sup>298</sup> specificity site in the hscLeuRS CP1 domain. On the basis of the structure of the hscLeuRS CP1 domain, we hypothesize that the tyrosine residue could flip into vacant space over the neighboring Val<sup>497</sup> (Figure 1B) to allow binding of the editing substrate.

Indeed, closure of the I4 lid might facilitate an induced fit mechanism for the hscLeuRS editing site that adequately includes the bulky Tyr<sup>298</sup> mutation.

The universal aspartic acid in the editing active site of the hscLeuRS is critical to tRNA deacylation as found for all other enzymes where it has been tested. Here, we demonstrated that an alanine substitution at the conserved site blocks deacylation activity *in vitro*. This is consistent with *in vivo* experiments showing that the introduction of a bulky positively charged lysine residue for the aspartic acid failed to protect yeast knockout cells from high concentrations of norvaline (31).

Surprisingly, the universally conserved aspartic acid in the CP1 domain was important to not only editing active site substrate interactions but also interactions with the amino acid in the synthetic active site. Substitution of the aspartic acid resulted in a long-distance  $K_M$  effect on the amino acid activation step, which would be expected to be governed primarily by the aminoacylation active site in the canonical core. Significantly, this long distance effect was selective for the cognate leucine amino acid, suggesting that the CP1 domain might also distally influence amino acid discrimination within the aminoacylation core.

Since aminoacylation activity is also decreased for the D399A hscLeuRS mutant, it is possible that tRNA mediates this distal amino acid discrimination effect in the synthetic site. In this case, tRNA would be expected to bind in the so-called "exit/entry" position where its 3' end is near the editing active site (32, 33). Translocation of the tRNA could be slowed as it sweeps through the altered editing active site en route to the aminoacylation active site. However, these long-distance effects were also detected in the absence of tRNA during pyrophosphate exchange assays. Thus, subtle changes in the editing active site must be transmitted via nodes within the protein itself to influence amino acid activation (34).

The D399A hscLeuRS mutant only exhibited weak mischarging activity relative to other corresponding LeuRS, IleRS, and ValRS mutants, where post-transfer editing activity was completely abolished. Since the kinetic parameters for isoleucine activation were similar to those of the wild-type and mutant LeuRS, we hypothesize that the tRNA plays a significant role in maintaining fidelity. Indeed, mischarging activity seemed to be particularly sensitive to the presence of tRNA modifications and the origin of the tRNA. Ironically, *E. coli* crude tRNA yielded greater levels of mischarged tRNA. However, this could be because the *E. coli* tRNA was missing important elements that were embodied in the mammalian calf liver tRNA, which minimized mischarging of isoleucine by LeuRS. If this were the case, we hypothesize that the human enzyme relies, at least in part, on pretransfer editing that originates from the aminoacylation active site. A redundant mechanism for amino acid editing that originates in the aminoacylation active site would allow fidelity to be rescued in the absence of post-transfer editing activity in the CP1 domain.

The hscLeuRS is part of a large macromolecular complex that includes nine aaRSs and three small auxiliary proteins (35, 36). A cryo-EM structure for the multi-aaRS complex has been determined at 30 Å and shows that this large complex is approximately 19 nm × 16 nm × 10 nm (21, 37). Although the 3.25 Å X-ray crystal structure of the human cytoplasmic LeuRS CP1 domain has also been determined (22), it is unclear how this editing domain and the remainder of the human LeuRS fit into the macromolecular complex. In the context of the multi-aaRS complex, it is possible that domain motions such as the CP1 domain might be constrained. In this case, redundant fidelity

pathways may also serve as a more efficient amino acid editing mechanism that does not require translocation of the mischarged tRNA to another editing domain. Recently, we showed that in the absence of the CP1 domain for *E. coli* and yeast mitochondrial LeuRS, the enzyme maintained fidelity by targeting the activated adenylate intermediate (38). In this case, isoleucyl adenylate could be hydrolyzed within the aminoacylation active site (39) or selectively released for hydrolysis in the cellular milieu (40). Redundant mechanisms in amino acid editing could be essential to maintaining a level of protein synthesis fidelity, particularly in mammals that would guard against neurological disease (7).

We hypothesize that some of the architectural and mechanistic differences that are specific to hscLeuRS may have been acquired in part because of its association with the multi-aaRS complex. These differences have likely facilitated discovery of a novel class of benzoxaborole antifungal compounds, which are in development for the treatment of onychomycosis. In particular, AN3018 inhibits yeast cytoplasmic LeuRS by forming a covalent adduct with the 3' adenosine of the tRNA<sup>Leu</sup> to trap it in the editing site (32). Significantly though, complementation experiments using yeast knockout tester strains have indicated that the hscLeuRS is susceptible to AN2690 (31). Furthermore, the D399K hscLeuRS editing-deficient mutant is resistant to AN2690 in complemented yeast cells (31), indicating the importance of the Asp<sup>399</sup> residue in hscLeuRS for binding within the editing site. The AN2690 inhibitor appears to bind to the human enzyme in these yeast complementation assays, in spite of crystal structure analysis of the hscLeuRS CP1 domain that suggests that the size of the hydrophobic editing pocket is smaller than that of the yeast enzyme (22). Nevertheless, a network of water molecules and an induced fit mechanism in the editing site could provide plasticity, especially in a version of hscLeuRS that is freed from its multi-aaRS macromolecular complex. It is also important to note that native residence within the multi-aaRS macromolecular complex might hinder inhibitor interactions with the hscLeuRS CP1 domain, particularly in a mechanism that requires cross-linking the large tRNA substrate that spans two protein domains.

## ACKNOWLEDGMENT

We are grateful to Anacor Pharmaceuticals for providing the plasmid expressing human cytoplasmic LeuRS. We thank Dr. Michal Boniecki for insightful discussions.

## REFERENCES

1. Ibba, M., and Söll, D. (2004) Aminoacyl-tRNAs: Setting the limits of the genetic code. *Genes Dev.* 18, 731–738.
2. Mascarenhas, A. P., An, S., Rosen, A. E., Martinis, S. A., and Musier-Forsyth, K. (2008) Fidelity mechanisms of the aminoacyl-tRNA synthetases. In *Protein Engineering* (RajBhandary, U. L., and Köhrer, C., Eds.) Springer-Verlag Inc., New York.
3. Hendrickson, T., and Schimmel, P. (2002) Transfer RNA-dependent amino acid discrimination by aminoacyl-tRNA synthetases. In *Translation Mechanisms* (Lapointe, J., and Brakier-Gingras, L., Eds.) Landes Bioscience, Georgetown, TX.
4. Karkhanis, V. A., Boniecki, M. T., Poruri, K., and Martinis, S. A. (2006) A viable amino acid editing activity in the leucyl-tRNA synthetase CP1-splicing domain is not required in the yeast mitochondria. *J. Biol. Chem.* 281, 33217–33225.
5. Karkhanis, V. A., Mascarenhas, A. P., and Martinis, S. A. (2007) Amino acid toxicities of *Escherichia coli* that are prevented by leucyl-tRNA synthetase amino acid editing. *J. Bacteriol.* 189, 8765–8768.
6. Nangle, L. A., Motta, C. M., and Schimmel, P. (2006) Global effects of mistranslation from an editing defect in mammalian cells. *Chem. Biol.* 13, 1091–1100.



7. Lee, J. W., Beebe, K., Nangle, L. A., Jang, J., Longo-Guess, C. M., Cook, S. A., Davisson, M. T., Sundberg, J. P., Schimmel, P., and Ackerman, S. L. (2006) Editing-defective tRNA synthetase causes protein misfolding and neurodegeneration. *Nature* **443**, 50–55.
8. Starzyk, R. M., Webster, T. A., and Schimmel, P. (1987) Evidence for dispensable sequences inserted into a nucleotide fold. *Science* **237**, 1614–1618.
9. Cusack, S., Yaremchuk, A., and Tukalo, M. (2000) The 2 Å crystal structure of leucyl-tRNA synthetase and its complex with a leucyl-adenylate analogue. *EMBO J.* **19**, 2351–2361.
10. Fersht, A. R., and Kaethner, M. M. (1976) Enzyme hyperspecificity. Rejection of threonine by the valyl-tRNA synthetase by misacylation and hydrolytic editing. *Biochemistry* **15**, 3342–3346.
11. Mursinna, R. S., and Martinis, S. A. (2002) Rational design to block amino acid editing of a tRNA synthetase. *J. Am. Chem. Soc.* **124**, 7286–7287.
12. Zhao, M. W., Zhu, B., Hao, R., Xu, M. G., Eriani, G., and Wang, E. D. (2005) Leucyl-tRNA synthetase from the ancestral bacterium *Aquifex aeolicus* contains relics of synthetase evolution. *EMBO J.* **24**, 1430–1439.
13. Betha, A. K., Williams, A. M., and Martinis, S. A. (2007) Isolated CP1 domain of *Escherichia coli* leucyl-tRNA synthetase is dependent on flanking hinge motifs for amino acid editing activity. *Biochemistry* **46**, 6258–6267.
14. Mursinna, R. S., Lincecum, T. L., Jr., and Martinis, S. A. (2001) A conserved threonine within *Escherichia coli* leucyl-tRNA synthetase prevents hydrolytic editing of leucyl-tRNA<sup>Leu</sup>. *Biochemistry* **40**, 5376–5381.
15. O'Donoghue, P., and Luthey-Schulten, Z. (2003) On the evolution of structure in aminoacyl-tRNA synthetases. *Microbiol. Mol. Biol. Rev.* **67**, 550–573.
16. Zhai, Y., Nawaz, M. H., Lee, K. W., Kirkbride, E., Briggs, J. M., and Martinis, S. A. (2007) Modulation of substrate specificity within the amino acid editing site of leucyl-tRNA synthetase. *Biochemistry* **46**, 3331–3337.
17. Lincecum, T. L., Jr., Tukalo, M., Yaremchuk, A., Mursinna, R. S., Williams, A. M., Sproat, B. S., Van Den Eynde, W., Link, A., Van Calenbergh, S., Grotli, M., Martinis, S. A., and Cusack, S. (2003) Structural and mechanistic basis of pre- and posttransfer editing by leucyl-tRNA synthetase. *Mol. Cell* **11**, 951–963.
18. Fukunaga, R., and Yokoyama, S. (2005) Structural basis for non-cognate amino acid discrimination by the valyl-tRNA synthetase editing domain. *J. Biol. Chem.* **280**, 29937–29945.
19. Bishop, A. C., Nomanbhoy, T. K., and Schimmel, P. (2002) Blocking site-to-site translocation of a misactivated amino acid by mutation of a class I tRNA synthetase. *Proc. Natl. Acad. Sci. U.S.A.* **99**, 585–590.
20. Tang, Y., and Tirrell, D. A. (2002) Attenuation of the editing activity of the *Escherichia coli* leucyl-tRNA synthetase allows incorporation of novel amino acids into proteins *in vivo*. *Biochemistry* **41**, 10635–10645.
21. Norcum, M. T., and Boisset, N. (2002) Three-dimensional architecture of the eukaryotic multisynthetase complex determined from negatively stained and cryoelectron micrographs. *FEBS Lett.* **512**, 298–302.
22. Seiradake, E., Mao, W., Hernandez, V., Baker, S. J., Plattner, J. J., Alley, M. R., and Cusack, S. (2009) Crystal structures of the human and fungal cytosolic leucyl-tRNA synthetase editing domains: A structural basis for the rational design of antifungal benzoxaboroles. *J. Mol. Biol.* **390**, 196–207.
23. Tocchini-Valentini, G., Saks, M. E., and Abelson, J. (2000) tRNA leucine identity and recognition sets. *J. Mol. Biol.* **298**, 779–793.
24. Sampson, J. R., and Uhlenbeck, O. C. (1988) Biochemical and physical characterization of an unmodified yeast phenylalanine transfer RNA transcribed *in vitro*. *Proc. Natl. Acad. Sci. U.S.A.* **85**, 1033–1037.
25. Puglisi, J. D., and Tinoco, I., Jr. (1989) Absorbance melting curves of RNA. *Methods Enzymol.* **180**, 304–325.
26. Schreier, A. A., and Schimmel, P. R. (1972) Transfer ribonucleic acid synthetase catalyzed deacylation of aminoacyl transfer ribonucleic acid in the absence of adenosine monophosphate and pyrophosphate. *Biochemistry* **11**, 1582–1589.
27. Hsu, J. L., Rho, S. B., Vannella, K. M., and Martinis, S. A. (2006) Functional divergence of a unique C-terminal domain of leucyl-tRNA synthetase to accommodate its splicing and aminoacylation roles. *J. Biol. Chem.* **281**, 23075–23082.
28. Liu, Y., Liao, J., Zhu, B., Wang, E. D., and Ding, J. (2006) Crystal structures of the editing domain of *Escherichia coli* leucyl-tRNA synthetase and its complexes with Met and Ile reveal a lock-and-key mechanism for amino acid discrimination. *Biochem. J.* **394**, 399–407.
29. Fukunaga, R., and Yokoyama, S. (2005) Crystal structure of leucyl-tRNA synthetase from the archaeon *Pyrococcus horikoshii* reveals a novel editing domain orientation. *J. Mol. Biol.* **346**, 57–71.
30. Zhai, Y., and Martinis, S. A. (2005) Two conserved threonines collaborate in the *Escherichia coli* leucyl-tRNA synthetase amino acid editing mechanism. *Biochemistry* **44**, 15437–15443.
31. Yao, P., Zhou, X. L., He, R., Xue, M. Q., Zheng, Y. G., Wang, Y. F., and Wang, E. D. (2008) Unique residues crucial for optimal editing in yeast cytoplasmic leucyl-tRNA synthetase are revealed by using a novel knockout yeast strain. *J. Biol. Chem.* **283**, 22591–22600.
32. Rock, F. L., Mao, W., Yaremchuk, A., Tukalo, M., Crepin, T., Zhou, H., Zhang, Y. K., Hernandez, V., Akama, T., Baker, S. J., Plattner, J. J., Shapiro, L., Martinis, S. A., Benkovic, S. J., Cusack, S., and Alley, M. R. (2007) An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. *Science* **316**, 1759–1761.
33. Hellmann, R. A., and Martinis, S. A. (2009) Defects in transient tRNA translocation bypass tRNA synthetase quality control mechanisms. *J. Biol. Chem.* **284**, 11478–11484.
34. Sethi, A., Eargle, J., Black, A. A., and Luthey-Schulten, Z. (2009) Dynamical networks in tRNA:protein complexes. *Proc. Natl. Acad. Sci. U.S.A.* **106**, 6620–6625.
35. Han, J. M., Kim, J. Y., and Kim, S. (2003) Molecular network and functional implications of macromolecular tRNA synthetase complex. *Biochem. Biophys. Res. Commun.* **303**, 985–993.
36. Kaminska, M., Havrylenko, S., Decottignies, P., Gillet, S., Le Marechal, P., Negrutskii, B., and Mirande, M. (2009) Dissection of the structural organization of the aminoacyl-tRNA synthetase complex. *J. Biol. Chem.* **284**, 6053–6060.
37. Norcum, M. T., and Warrington, J. A. (1998) Structural analysis of the multienzyme aminoacyl-tRNA synthetase complex: A three-domain model based on reversible chemical crosslinking. *Protein Sci.* **7**, 79–87.
38. Boniecki, M. T., Vu, M. T., Betha, A. K., and Martinis, S. A. (2008) CP1-dependent partitioning of pretransfer and posttransfer editing in leucyl-tRNA synthetase. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 19223–19228.
39. Gruic-Sovulj, I., Uter, N., Bullock, T., and Perona, J. J. (2005) tRNA-dependent aminoacyl-adenylate hydrolysis by a nonediting class I aminoacyl-tRNA synthetase. *J. Biol. Chem.* **280**, 23978–23986.
40. Hati, S., Ziervogel, B., Sternjohn, J., Wong, F. C., Nagan, M. C., Rosen, A. E., Siliciano, P. G., Chihade, J. W., and Musier-Forsyth, K. (2006) Pre-transfer editing by class II prolyl-tRNA synthetase: Role of aminoacylation active site in “selective release” of noncognate amino acids. *J. Biol. Chem.* **281**, 27862–27872.